Fortress Biotech Q2 EPS $(0.73) Beats $(1.23) Estimate, Sales $14.90M Beat $14.77M Estimate
Portfolio Pulse from Benzinga Newsdesk
Fortress Biotech (NASDAQ:FBIO) reported Q2 EPS of $(0.73), beating the $(1.23) estimate, and sales of $14.90M, beating the $14.77M estimate. EPS improved by 80% YoY, while sales decreased by 14.32% YoY.
August 13, 2024 | 8:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fortress Biotech reported better-than-expected Q2 EPS of $(0.73) and sales of $14.90M. EPS improved significantly YoY, but sales declined.
The better-than-expected EPS and sales figures are likely to positively impact FBIO's stock price in the short term. The significant improvement in EPS is a strong positive signal, despite the YoY decline in sales.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100